Alzheimer's drug Leqembi may help over 75% people remain stable or…
A real-world study found that most patients receiving the anti-amyloid therapy Leqembi (lecanemab) remained clinically stable after 17 months, with 75.9% remaining at the same stage and 6.6% improving by 1 disease stage, for an overall 82.5% stable or …